key: cord-0923626-r4y7pix3 authors: Wei, Tan See title: Cutaneous Reactions to COVID-19 Vaccines: A Review date: 2022-02-17 journal: JAAD Int DOI: 10.1016/j.jdin.2022.01.011 sha: efd3dd48f0f1bb43dbf4b369b2cc549091fc7645 doc_id: 923626 cord_uid: r4y7pix3 Background The increasing number of reports on cutaneous reactions following coronavirus disease (COVID-19) vaccination has led to growing concerns among certain groups. Objective We reviewed published reports of cutaneous lesions after COVID-19 vaccination. Methods We conducted a literature search for original and review articles published between January 1, 2020, and September 27, 2021. Results Eleven cutaneous reactions associated with COVID-19 vaccines were determined; the most prevalent reactions were local injection site reactions, delayed local reactions, urticaria, angioedema, and morbilliform eruptions. There were more reports on skin reactions following mRNA-based vaccines compared to adenoviral vector or inactivated whole-virus vaccines, in part due to their higher administration rate. Most reported skin reactions occurred after the first vaccination dose. Limitations Reporting bias cannot be excluded, and skin biopsy results were not available for most included individuals. Moreover, given that the included trials focused on vaccine efficacy, there was a lack of details concerning cutaneous reactions and participant information. Conclusion Not all cutaneous reactions observed after COVID-19 vaccination are hypersensitivity reactions. Different cutaneous reactions may reflect underlying immune responses to vaccines. A large majority of COVID-19 vaccination reactions were mild and self-limiting, and people should be encouraged to complete their vaccination regimen. As coronavirus disease mass vaccination is underway, increasing reports of adverse reactions 56 associated with the vaccines are emerging. Anecdotal reports regarding novel formulations of 57 mRNA-based vaccines are inflated by social media, generating alarming misconceptions about 58 accounted for 0.04% of the reported skin reactions following COVID-19 vaccination. All the 149 reported bullous eruptions occurred after mRNA vaccination and most (60%) occurred after the 150 first dose. The median age of individuals who developed bullous eruptions after vaccination was 79 years (men: 50%; women: 50%). The median duration for onset of bullous 152 eruptions following COVID-19 vaccination was 7 days. 153 8. Filler reactions: Filler reactions refer to the delayed inflammatory reactions to hyaluronic acid-154 based fillers. They manifest as erythema, painful induration, tissue hardening, and edema. (13, 14) 155 Filler reactions accounted for 0.04% of the reported skin reactions following vaccination. All the reported filler reactions occurred after mRNA vaccination. In total, 50% 157 occurred after the first dose and 50% after the second dose. The median age of individuals who 158 experienced filler reactions was 47 years; 50% of them were women, while 50% did not report 159 their age or sex. The median duration for onset of filler reactions following COVID-19 vaccination 160 was 1 day. 161 9. Chilblains: Chilblains accounted for 0.03% of the reported skin reactions. All the reported cases 162 of chilblains occurred after mRNA vaccination and most (64%) occurred after the first dose. The 163 median age of individuals who experienced chilblains was 70 years. The median duration for 164 onset of chilblains following COVID-19 vaccination was 3 days. 165 10. Pityriasis rosea: In total, 0.023% of the reported skin reactions following COVID-19 vaccination 166 were attributed to pityriasis rosea. Most (90%) occurred after mRNA vaccination and after the 167 second dose (60%). The median age of individuals who experienced pityriasis rosea was 39 168 years; among them, 40% were women, 20% were men, and 40% did not report their age or sex. 169 The median duration for onset of the eruptions of pityriasis rosea following COVID-19 170 vaccination was 5.5 days. 171 J o u r n a l P r e -p r o o f 11. Severe cutaneous adverse reactions (SCARs) following COVID-19 vaccination were very rare and 172 accounted for 0.004% (two cases) of the reported skin reactions (15, 16) . Nonetheless, they posed 173 a significant risk of morbidity and mortality in affected patients. The reported SCARs included 174 acute generalized exanthematous pustulosis and Steven-Johnson syndrome. The two reported 175 cases occurred after adenoviral vector vaccines. The median age of the individuals who 176 experienced SCARs was 67 years and both were male. The median duration for onset of SCARs 177 following COVID-19 vaccination was 3 days. Both patients recovered with no serious sequelae. 178 Other less common cutaneous reactions reported following COVID-19 vaccination included erythema 180 multiforme (0.02%), (17) (18) (19) (20) (21) (22) (23) (24) Sweet syndrome (0.012%), (18, (25) (26) (27) (28) dermal hypersensitivity reactions (0.01%), (17) 181 lichen planus (0.006%), (29, 30) papulo-vesicular eruptions (0.006%), (17) pityriasis-rosea like eruptions 182 (0.004%), (31, 32) generalized annular lesions (0.002%), (33) facial pustular neutrophilic eruptions (0.004%), (34) The increasing number of reports of cutaneous reactions following mRNA vaccination has led to 194 misinformation in the media. (1, 2) Misleading claims arise from relatively short clinical trials and the novel 195 mechanisms of mRNA vaccines. We sought to explore the skin reactions occurring after Local injection site reactions were more commonly observed in younger individuals than in older 198 individuals. (3, 4) To date, no serious sequelae have been reported in individuals with local injection site 199 reactions. By providing proper vaccine guidance, recipients will be mentally prepared for the possible 200 occurrence of cutaneous reactions and, therefore, more likely to complete their second dose. 201 In observational studies, delayed local reactions were the most commonly reported cutaneous reactions 202 following COVID-19 vaccination. Nearly all of these reactions occurred after mRNA vaccination, with a 203 few occurring after DNA vaccination. (3, 4, 6, 9, 10, The mechanism of these reactions is not fully 204 understood. Skin biopsy results in these individuals support the speculation of T cell-mediated 205 hypersensitivity as the mechanism of delayed injection site reactions. (59) Delayed hypersensitivity 206 reactions are expected to occur sooner and robustly after the second vaccine dose than after the first 207 dose owing to prior sensitization. However, most delayed local reactions to the first dose did not recur 208 with the second dose. (4, 7, 60) 209 Another hypothesis is related to the delayed appearance of the spike protein; mRNA vaccines require 210 translation of the mRNA to generate endogenously produced viral spike proteins to which the immune 211 response is generated. Similarly, antigen production in adenoviral vector-based vaccines is delayed, 212 because the vaccine is delivered within a viral envelope, and the host cells start producing spike proteins 213 in a similar manner as after an mRNA vaccination. (61) The immune response generated after the first 214 dose could moderate the subsequent reaction to the second dose. The timing of delayed local reaction 215 onset coincides with that of the immune response's detection of the spike protein generated by the 216 vaccine's mRNA at the injection site. (62, 63) Delayed local reactions to COVID-19 vaccines may reflect the 217 protective immune response stimulated by the vaccine. Given the similarities in appearance and timing 218 of onset, these delayed local reactions have been misdiagnosed as cellulitis. (64, 65) proposed the use of lisinopril to treat the delayed filler reactions after COVID-19 243 vaccination, which was deemed beneficial. The authors theorized that blocking the production of 244 angiotensin II reduces the ACE2 substrate; thus, ACE inhibitors will promote an anti-inflammatory 245 response. (13, 72) 246 There are reported cases of pityriasis rosea eruption following COVID-19 vaccination. One of the 247 hypotheses regarding this association is that a high cytokine response to the vaccine may distract the T-248 cell-mediated control of latent infections, such as human herpesvirus 6 and 7; hence, the reactivation of 249 latent viruses. (73) (74) (75) In contrast, pityriasis rosea-like eruptions following COVID-19 vaccination may have a 250 different pathophysiology. They are postulated to be a manifestation of a delayed hypersensitivity 251 response to the vaccine. (76) 252 This literature review had some limitations. First, the focus of the included clinical trials is predominantly 253 on vaccine efficacy; therefore, there is a lack of details regarding cutaneous reactions and participant 254 information. Second, most of the included individuals did not undergo skin biopsy; it is challenging to 255 differentiate causality from causation in some of the cutaneous manifestations without histological 256 results. Third, reporting bias cannot be excluded. 257 In conclusion, this review presents a spectrum of cutaneous reactions following COVID-19 vaccination. 258 Most reactions were self-limiting and should not discourage vaccination. We observed that cutaneous 259 reactions following mRNA-based vaccination were more commonly reported than that those after 260 inactivated whole-virus vaccination. This could be due to the widespread use of mRNA-based vaccines. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 2021 (14) , case series BNT162b2 Case 1: 11.5 days No serious sequelae reported 2021 (72) , case series n=6 50%) case report BNT162b2 *Skin biopsy: Perivascular and interstitial lymphocytic inflammatory infiltrate with associated interface dermatitis and necrotic keratinocytes 2021 (102) , case report BNT162b2, n=1 1/1 (100%) Age: 82 Gender: 1F Dose 1: 1/1 (100%) Dose 1: 1 day No serious sequelae reported registrybased study n=597 Dose 1: 3/4 (75%) Dose 2: 1/4 (25%) NR No serious sequelae reported 47 Gender: 1F Dose 1: -Dose 2: 1/1 (100%) Dose 1: -Dose 2: 1 day No serious sequelae reported *Skin biopsy: Superficial and interstitial perivascular dermatitis with lymphohistiocytic infiltrate an the presence of eosinophils. Laboratory: eosinophilia Dermal hypersensitivity eruptions 2021 (30) , case report BNT162b2, n=1 1/1 (100%) Age: 56 Gender: 1F Dose 1: 1/1 (100%) Dose 2: -7 days No serious sequelae reported. *Skin biopsy: compact hyperkeratosis, hypergranulosis, irregular epidermal hyperplasia and lichenoid lymphocytic infiltrate 2021 (31) , case series BNT162b2 Pustules: Sterile with no bacterial growth /1 (100%) Dose 1: 1/1 (100%) Dose 1: 2 days Recovered antihistamines and topical steroids *Skin biopsy: Mixed spongiotic and interface dermatitis with rare eosinophils and extravasated erythrocytes